EdgePoint reports 8.8% Twist Bioscience (TWST) ownership stake

Rhea-AI Filing Summary

EdgePoint Investment Group Inc. reported a significant ownership position in Twist Bioscience Corp common stock. As of December 31, 2025, EdgePoint beneficially owned 5,377,991 shares, representing 8.80% of the outstanding common stock.

EdgePoint, an investment adviser based in Ontario, Canada, has sole voting and dispositive power over 4,165,651 shares and shared voting and dispositive power over 1,212,340 shares. The stake is held in the ordinary course of business and not for the purpose of changing or influencing control of Twist Bioscience.

02/17/2026 - 04:21 PM

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Twist Bioscience Corp

(Name of Issuer)

Common stock, $0.00001 par value per share

(Title of Class of Securities)

90184D100

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 90184D100

1

Names of Reporting Persons

EdgePoint Investment Group Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

ONTARIO, CANADA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 4,165,651.00
6	Shared Voting Power 1,212,340.00
7	Sole Dispositive Power 4,165,651.00
8	Shared Dispositive Power 1,212,340.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

5,377,991.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

8.80 %

12

Type of Reporting Person (See Instructions)

IA, FI

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Twist Bioscience Corp
(b)	Address of issuer's principal executive offices: 681 Gateway Blvd, South San Francisco, CA 94080
Item 2.
(a)	Name of person filing: This Schedule 13G is being filed on behalf of EdgePoint Investment Group Inc. ("EdgePoint") with respect to the Common Stock, with $0.00001 par value per share ("Common Stock"), of Twist Bioscience Corp (the "Issuer"). EdgePoint acts as investment manager to, and exercises investment discretion with respect to the Common Stock directly owned by, a number of private investment funds and mutual fund trusts.
(b)	Address or principal business office or, if none, residence: 150 Bloor Street West, Suite 700, Toronto, Ontario M5S 2X9, Canada
(c)	Citizenship: Ontario, Canada
(d)	Title of class of securities: Common stock, $0.00001 par value per share
(e)	CUSIP No.: 90184D100
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
	NA
Item 4.	Ownership
(a)	Amount beneficially owned: 5,377,991.00
(b)	Percent of class: 8.80%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 4,165,651
	(ii) Shared power to vote or to direct the vote: 1,212,340
	(iii) Sole power to dispose or to direct the disposition of: 4,165,651
	(iv) Shared power to dispose or to direct the disposition of: 1,212,340
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

EdgePoint Investment Group Inc.

Signature:	Sayuri Childs
Name/Title:	Sayuri Childs | Chief Compliance Officer
Date:	02/17/2026

FAQ

How many Twist Bioscience (TWST) shares does EdgePoint Investment Group own?

EdgePoint Investment Group beneficially owns 5,377,991 shares of Twist Bioscience common stock. This position reflects its role as investment manager for various private investment funds and mutual fund trusts that directly hold the shares on whose behalf EdgePoint exercises investment discretion.

What percentage of Twist Bioscience (TWST) does EdgePoint Investment Group control?

EdgePoint Investment Group reports beneficial ownership of 8.80% of Twist Bioscience’s common stock. This percentage is based on the company’s outstanding common shares and indicates a sizable institutional stake, though still a minority position within the overall shareholder base.

How much voting power does EdgePoint have in Twist Bioscience (TWST)?

EdgePoint has sole voting power over 4,165,651 shares and shared voting power over 1,212,340 shares of Twist Bioscience. This structure reflects shares held across multiple funds where EdgePoint either independently or jointly directs how the shares are voted.

Is EdgePoint Investment Group seeking control of Twist Bioscience (TWST)?

EdgePoint states the Twist Bioscience shares were acquired and are held in the ordinary course of business, not to change or influence control of the company. The position is described as an investment, rather than part of any control-focused transaction or campaign.

Who signed the Twist Bioscience (TWST) Schedule 13G/A for EdgePoint?

The Schedule 13G/A was signed by Sayuri Childs, Chief Compliance Officer of EdgePoint Investment Group Inc. The signature certifies, after reasonable inquiry, that the information reported about EdgePoint’s beneficial ownership of Twist Bioscience shares is true, complete, and correct.

What type of entity is EdgePoint Investment Group in relation to Twist Bioscience (TWST)?

EdgePoint Investment Group is identified as an investment adviser (Type IA). It acts as investment manager and exercises investment discretion over Twist Bioscience shares held by several private investment funds and mutual fund trusts for which it manages portfolios.